HUGOTON ROYALTY TRUST DECLARES NO OCTOBER CASH DISTRIBUTION

Argent Trust Company, as Trustee of theHugoton Royalty Trust (the “Trust”) (OTCQB: HGTXU) announced today there would not be a cash distribution to the holders of its units of beneficial interest for October 2024 due to the excess cost positions on all three of the Trust’s conveyances of net profits interests. The Trust’s cash reserve […]

CROSS TIMBERS ROYALTY TRUST DECLARES OCTOBER CASH DISTRIBUTION

Argent Trust Company, as Trustee of the Cross Timbers Royalty Trust (the “Trust”) (NYSE: CRT), today declared a cash distribution to the holders of its units of beneficial interest of $0.064592 per unit, payable on November 15, 2024, to unitholders of record on October 31, 2024. The following table shows underlying oil and gas sales

Cumulus Media Announces Conference Call to Discuss Third Quarter 2024 Operating Results

ATLANTA, Oct. 21, 2024 (GLOBE NEWSWIRE) — Cumulus Media Inc. (NASDAQ: CMLS) will host a conference call on Friday, November 1st at 8:30 AM ET to discuss its third quarter 2024 operating results. A press release containing a summary of these results will be issued before the call at approximately 8:00 AM ET. To participate

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Company highlights its path to success for 2025 BERKELEY, Calif. and

PERMIAN BASIN ROYALTY TRUST ANNOUNCES OCTOBER CASH DISTRIBUTION

Argent Trust Company, as Trustee of the Permian Basin Royalty Trust (NYSE: PBT) (“Permian” or the “Trust”) today declared a cash distribution to the holders of its units of beneficial interest of $0.029986 per unit, payable on November 15, 2024, to unit holders of record on October 31, 2024. The distribution does not include proceeds

ProPharma Appoints Brian Tuttle as Chief Financial Officer

Seasoned Life Sciences Executive to Spearhead Financial Strategy and Drive Accelerated Growth ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners, today announced that Brian Tuttle has been named Chief Financial Officer. https://mma.prnewswire.com/media/2534186/Brian_Tuttle.jpg Tuttle brings over 20 years of financial

Calamos Announces Upside Cap Range for Upcoming Structured Protection ETF Providing Exposure to S&P 500 with 100% Downside Protection Over One Year

— The Calamos S&P 500® Structured Alt Protection ETF™ – November (CPSN) is slated to launch November 1, 2024 with an estimated upside cap range of 6.39% – 7.01% over a one-year outcome period. — TheCalamos Structured Protection ETF™ suite combines Calamos’ decades-long alternatives, risk management and options investing expertise with the liquid, cost-effective and

Tecsys Enhances Supply Chain Performance with Advanced Data Science and Technology Tools in Latest Release

Data-driven operational control and efficiency prominently featured in Elite™ 24.2 release Tecsys Inc.(TSX: TCS), a global leader in supply chain management solutions, has introduced new advanced capabilities in its Elite™ software platform that help businesses achieve a greater degree of supply chain efficiency and resilience. These innovations, part of the Elite 24.2 release, empower supply

LoanCare Expands with Digital Recapture, Paving the Way for Lender Success

LoanCare®, a leading national mortgage subservicer, announced today the launch of Digital Recapture. The new suite of tools connects homeowners with lending products that help inform them about potential home equity or lower interest rates, while keeping their lending partner top of mind. https://mma.prnewswire.com/media/2334584/LoanCare_Logo.jpg LoanCare’s Digital Recapture provides lenders with a streamlined process to engage

Orsini Is Now a Specialty Pharmacy Provider for FUROSCIX® (furosemide injection), an Infused Diuretic for Congestive Heart Failure

Orsini announced today that it has been chosen by scPharmaceuticals to distribute FUROSCIX® (furosemide injection)80 mg/10mL for subcutaneous use, indicated for the treatment of congestion due to fluid overload in adults with chronic heart failure. FUROSCIX is a single-use infused diuretic that can be administered at home by patients and caregivers. View the full Prescribing

Scroll to Top